Clinical Trial Update: Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update notes ongoing Phase 1/2 safety testing of a single and repeat dose of PYC-001 eye injections in people with Autosomal Dominant Optic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Optic Atrophy
• Hereditary Optic Atrophy
• Kjer Optic Atrophy

Drugs mentioned

• PYC-001 Eye Injections

Snippet

Sponsor: PYC Therapeutics | Conditions: OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy | Phase 1, Phase 2 | Status: RECRUITING